Shares of Cybin, Inc. ($CYBN) surged as much as 10% on Monday, reaching their highest level since May, following the ...

The US FDA has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treating acute leukaemia with KMT2A translocation.

As psychedelic medicine inches closer to mainstream acceptance, researchers have tackled a crucial question: How many ...

Music therapy reduces distress and improves well-being in advanced dementia by meeting unmet needs, enhancing ...

Nipocalimab is a fully human monoclonal antibody that blocks FcRn and decreases levels of circulating IgG antibodies.

A revolutionary breakthrough in cataract treatment is on the horizon, with the emergence of C-KAD, a new eye drop therapy.

A clinical trial has shown promising results in treating brain tumours in children using an immune-cell therapy known as ...

Johnson & Johnson announced that the U.S. Food and Drug Administration has granted nipocalimab Breakthrough Therapy designation for the ...

Researchers from the Center for Regenerative Medicine (CReM) and the Department of Medicine at Boston Medical Center (BMC) ...

A Seattle biotech company is working on a tweak to gene expression that could shut down hepatitis B (HBV), one of the viruses ...

Johnson & Johnson said its nipocalimab treatment for adults living with moderate-to-severe Sjögren's disease has received breakthrough therapy designation from the Food and Drug Administration.

Canadian cancer researchers are part of global efforts to test targeted alpha therapy, a new form of treatment that some ...